MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-18-2026
Processa Pharmaceuticals Operating Cash Flow 2011-2026 | PCSA
Annual Operating Cash Flow Processa Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11.4 M | -11.2 M | -8.06 M | -9.61 M | -8.72 M | -3.14 M | -2.75 M | -3.71 M | -1.65 M | -2.16 M | -872 K | -2.69 M | -2.54 M | -1.89 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -872 K | -11.4 M | -5.03 M |
Quarterly Operating Cash Flow Processa Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -2.73 M | - | - | - | -2.05 M | - | - | - | -2.11 M | - | -7.11 M | -4.13 M | -1.8 M | - | -5.99 M | -4.44 M | -2.24 M | - | -868 K | -897 K | -546 K | - | -2.14 M | -1.41 M | -607 K | - | -3.24 M | -2.23 M | -1.07 M | - | -979 K | -356 K | -58.7 K | - | -36.2 K | -52.9 K | -50.4 K | - | -826 K | -779 K | -502 K | - | -2.24 M | -1.7 M | -988 K | - | -2.08 M | -1.37 M | -593 K | - | -1.24 M | -588 K | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -36.2 K | -7.11 M | -1.72 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-8.24 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
MannKind Corporation
MNKD
|
18.3 M | $ 3.56 | 24.48 % | $ 1.09 B |  USA |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K | USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Bio-Techne Corporation
TECH
|
288 M | $ 47.41 | -16.36 % | $ 7.47 B | USA |
 |
United Therapeutics Corporation
UTHR
|
1.56 B | $ 596.76 | 4.29 % | $ 26.4 B | USA |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B | France |
 |
Athira Pharma
ATHA
|
-45.7 M | - | - | $ 269 M | USA |
 |
BioNTech SE
BNTX
|
890 M | - | - | $ 27.2 B | Germany |
 |
Checkmate Pharmaceuticals
CMPI
|
-53.7 M | - | - | $ 231 M | USA |
 |
INmune Bio
INMB
|
-22.6 M | $ 1.52 | -1.3 % | $ 37.6 M | USA |
 |
Exelixis
EXEL
|
884 M | $ 48.7 | 9.64 % | $ 13.2 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
158 M | $ 21.48 | -3.89 % | $ 3.56 B | USA |
 |
Fortress Biotech
FBIO
|
-65.8 M | - | - | $ 71.1 M | USA |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
-13.1 M | $ 3.15 | 1.19 % | $ 655 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.95 M | - | - | $ 5.51 M |  Israel |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
-116 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-38.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-5.62 M | $ 24.17 | 3.2 % | $ 3.08 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-19.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
Applied Therapeutics
APLT
|
-55.2 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-29.1 M | - | 17.91 % | $ 11.1 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-345 M | $ 55.08 | 5.15 % | $ 4.95 B |  Schweiz |
 |
Avenue Therapeutics
ATXI
|
-1.83 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-284 M | $ 1.7 | 3.66 % | $ 452 M | Britain |
 |
AVROBIO
AVRO
|
-63.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M | Israel |